Patients
melanoma, malignancy, cutaneous melanoma, autoimmune disease, Cancer
MELANOMA, CUTANEOUS MELANOMA, MUCOSAL MELANOMA, ONCOLOGY, SENTINEL NODE, AUTOIMMUNE DISEASE, CANCER
Patients ≥12 years of age with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 were eligible if they had histologically confirmed stage IIB or stage IIC cutaneous melanoma (per AJCC Cancer Staging Manual, 8th edition) that was completely resected, with wide excision margins and negative sentinel node biopsy (per local standard), within 12 weeks of randomization. Patients were excluded from the trial if they had any prior treatment for melanoma other than surgery, a history of ocular or mucosal melanoma, other prior malignancy within 3 years of randomization or autoimmune disease or any other condition requiring systemic immunosuppressive medications within 14 d of randomization. Full eligibility criteria are available in the protocol provided in the 